Piper Sandler Upgrades Teva Pharma (TEVA) to Overweight, 'The Times They Are A-Changin’'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
4 small and mid-cap biopharma stocks to own according to BofA
February 9, 2024 8:00 PM ESTBofA Global Research has published a new analysis of the US biopharmaceutical sector, highlighting their preferred small- and mid-cap (SMID) stock selections in this field.
From a broader perspective, BofA believes the fundamentals of the biopharma sector remain solid, evidenced by the productivity of research and development (R&D) and external validation through mergers and acquisitions (M&A) activity.
Thanks to favorable conditions within the industry, the outlook on the broader group has become more positive compared to previous years, analysts led by Jason M. Gerberry said.
Heading into 2024, we are... More
